Terkko Navigator / Aittokallio, T(ero)* (FIMM)

High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice

Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells

Tumor microenvironment as a metapopulation model: the effects of angiogenesis, emigration and treatment modalities

Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data

What are the current challenges for machine learning in drug discovery and repurposing?

Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS

Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses

Implementing a functional precision medicine tumor board for acute myeloid leukemia

Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS

Artificial intelligence for drug response prediction in disease models

Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia

Modeling drug combination effects via latent tensor reconstruction

Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS

Multi-Omics Marker Analysis Enables Early Prediction of Breast Tumor Progression

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia

Crowdsourced mapping of unexplored target space of kinase inhibitors

Erratum for Herring et al., "Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs"

Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor

Novel Small Molecule Hsp90/Cdc37 Interface Inhibitors Indirectly Target K-Ras-Signaling

Re-defining synthetic lethality by phenotypic profiling for precision oncology

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

Artificial intelligence, machine learning, and drug repurposing in cancer

Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs

Multiobjective optimization identifies cancer-selective combination therapies

Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer

Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling

Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine

A relational database to identify differentially expressed genes in the endometrium and endometriosis lesions

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses

KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia

Prediction of drug combination effects with a minimal set of experiments

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

Improved detection of differentially represented DNA barcodes for high-throughput clonal phenomics

Characterizing the Quality of Insight by Interactions: A Case Study

Breeze: an integrated quality control and data analysis application for high-throughput drug screening

SynergyFinder: a web application for analyzing drug combination dose-response matrix data

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine

Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1

<em>UBR5</em> Is Coamplified with <em>MYC</em> in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis

SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening

Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies

Genetic and functional implications of an exonic TRIM55 variant in heart failure

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival